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Summary Few data are available on the circadian rhythmicity in cancer patients. Since monitoring the disease
usually implies the follow-up of blood concentrations of a number of biological variables, it would be of value
to examine the profile of the circadian variations of serum cortisol and tumour marker antigens. This we did in
33 cancer patients (13 breast cancer patients and 20 ovarian cancer patients). The profiles of serum cortisol
were documented, since this hormone is considered as a strong marker of circadian rhythms. This study shows
that 8 out of 13 breast cancer patients and 15 out of 20 ovarian cancer patients had deeply altered cortisol
circadian patterns. The modifications were either high levels along the 24 h scale and/or erratic peaks and
troughs and/or flattened profiles. Within 24 h, variations of tumour marker antigens as large as 70% were
observed but no typical individual circadian patterns could be found. No relationship between cortisol
subgroups and concentration of tumour marker antigens at 8 h could be observed (Kolmogorov-Smirnov's
test). The question thus arises as to the origin of these alterations, and whether they are related to a cause or a
consequence of the disease, and their possible incidence upon therapeutic designs.
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All biological functions of human beings vary rhythmically
along the 24 h scale according to circadian rhythms (Touitou
and Haus, 1994; Reinberg and Smolensky, 1983). We
examined the circadian profiles of serum cortisol since this
hormone is considered as a strong marker of circadian
rhythms in humans (Haus and Touitou, 1994). Although
rhythmic sources of marker variability are of interest in
interpreting laboratory values and drug effects adequately,
few data are available in the literature on the circadian
rhythmicity of tumour marker antigens (Touitou et al., 1988;
Focan et al., 1986a, b). Cancer patients with so-called normal
blood levels of biological markers in the morning, at the
usual time of sampling (08.00), may actually have alteration
of the pattern of the marker rhythm resulting in higher levels
at other times in the 24 h scale. We therefore considered it
would be of value to document the circadian patterns of
carcinoembryonic antigen (CEA) and CA 15-3 in breast
cancer patients and of CEA and CA 125 in ovarian cancer
patients. Indeed, the question arises of the origin of rhythm
alterations, if any, in cancer patients since it could be either a
consequence or a cause (among others) of the disease and
besides, individual rhythmic characteristics might be a
criterion of selection for chronotherapy trials.
Patients
Thirty-three cancer patients were documented on a circadian
basis. Thirteen breast cancer patients volunteered for this
study: all had histologically proven metastatic breast
adenocarcinoma. All had previously received one, two or
three first-line chemohormonotherapy regimens with or
without radiotherapy and all had measurable disease. Their
mean age+s.d. was 52+9 years. All had received previous
treatment with doxorubicin (mean cumulative dose,
280 mg m 2, 0-500) and/or THP, a new anthracycline
analogue (mean cumulative dose, 80 mg m-2, 0-800).
Metastatic sites included bones (10/13), liver (7/13), skin
and lymph nodes (4/13), lung (2/13), bone marrow (1) and/or
choroid (1). Twenty ovarian cancer patients (55 + 12 years;
mean+s.d.) were also volunteers for this study. The disease
was stage Ia -IV. Eight patients received previous che-
motherapy.
The patients were informed of the nature and aims of this
study and gave their written informed consent. A physical
examination (including electrocardiogram), a chest radio-
graph and a biological work-up were performed. Character-
istics of the patients and basal values at 08.00 of serum
tumour markers and cortisol are presented in Table I.
Methods
For obvious ethical reasons, blood samples were taken only
every 4 h over 24 h for each patient; they were allowed to
clot and the serum was aspirated, aliquoted and frozen at
-200C until analysed. For a determined variable, all the
samples were assayed in a single series to avoid differences
between assays.
Serum cortisol was determined by radioimmunoassay
(RIA) (Travenol, Paris). Serum CEA and CA 125 were
determined by enzyme immunoassay (EIA) (Abbott, Rungis,
France) and serum CA 15-3 by Immunoradiometric assay
(IRMA) (CIS biointernational, Gif-sur-Yvette, France).
The intra-assay coefficients of variation were as follows:
CEA, 7.5 and 3.5% for concentrations of 6.7 and
102.0 ng ml-' respectively; CA 15-3, 7.3 and 6.4% for
concentrations of 27 and 75 U ml-' respectively; CA 125,
13.9% for a concentration of 47 U ml-'; cortisol, 3.2 and
4.4% for concentrations of 11.6 and 39.1 jug dl-' respectively.
Individual profiles were drawn after classifying the subjects
into subgroups with high and low serum levels of tumour
marker antigens on the one hand and according to so-called
normal and abnormal circadian profiles of serum cortisol on
the other hand. A circadian profile of serum cortisol was
considered as normal when it displayed a high morning
concentration around 08.00, and a decline with the lowest
concentrations between 20.00 and 00.00. It was considered as
abnormal when it was, for example, constantly high or low or
presented erratic peaks or troughs.
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Table I Characteristics of breast and ovarian cancer patients
Age Performance CEA CA 15-3 Cortisol
(years) statusa Stage(ng mrl) (U mrl)(jig drl)
Breast cancer
patients
1 BR 50 1 108 440 9.7
2 DB 60 1 2.4 62 25.5
3 DM 36 2 18.2 49 8.4
4 DS 47 1 28.4 292 1.5
5 FC 52 1 2.3 56 15.0
6 GS 45 1 52 242 6.1
7 JE 73 4 4.3 48 20.5
8 JL 50 4 9.1 90 16.0
9 LC 57 2 7.6 200 23.5
10 MT 58 3 18.5 400 33.0
11 MP 44 1 110 90 13.5
12 NC 48 0 49.5 430 14.0
13 SF 57 1 336 490 17.5
Ovarian
cancer patients
1 AUB 60 1 IlIb 1.6 51 7.9
2 BER 67 3 IV 0.5 272 6.1
3 BRO 58 1 IlIb ND 417 10.9
4 CAI 78 2 IlIb 141 83 7.9
5 COU 69 2 IIIb 2.5 412 30.4
6 DER 43 1 IIIb 0.6 211 21.5
7 ELL 47 2 IIIb ND 20 17.5
8 FAU 36 1 IlIb ND 51 7.7
9 FER 57 2 TIlb 0.8 19 16.9
10 FOU 36 1 IIlb 2.1 85 13.0
11 FRA 59 1 IV ND 252 24.4
12 GOU 36 1 Illb 1.1 21 24.2
13 LAM 67 2 IIIb ND 66 24.7
14 MAH 53 1 IIIb ND 152 0.8
15 MAR 61 2 IlIb 2.0 141 12.5
16 NIC 65 2 IIIb ND 300 21.4
17 PAL 56 1 IIIa ND 39 12.2
18 POR 74 2 IIIa ND 23 19.3
19 PUS 67 2 Illb ND 31 23.7
20 RIO 47 1 Ila ND 8 6.2
Concentration of serum variables are given at 08.00. ND, not
determined. ao, normal; 1, near normal; 2, needs bed rest for <50% of
time; 3, needs bed rest for >50% oftime; 4, bedridden, needs help to
perform normal activities.
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Figure 1 Patterns of serum cortisol in 13 patients with breast
cancer. (a) Normal profiles (n=5). (b) Abnormal profiles (n=7).
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Possible relationships between tumour marker concentra-
tions at 08.00 and the classification according to cortisol
serum profile were examined for using Kolmogorov-
Smirnov's non-parametric test. Indeed, in clinical usage
blood samples are drawn most often around 08.00 and the
purpose was to find out if greater morning concentrations of
tumour marker antigens could be an index of abnormal
cortisol pattern.
Results
Twenty-four h profiles of cortisol
As shown in Table I, serum cortisol concentrations at 08.00
were low in nine patients out of 33 (range: 0.8-8.4 jig dl-1).
Figures 1 and 2 display the individual profiles of cortisol in
breast cancer patients and in ovarian cancer patients
respectively.
In breast cancer patients, serum cortisol patterns were
found abnormal in eight out of 13 patients who presented
either a flattened profile or a shift in the peak or the trough
time, or a plateau with high values during the morning
(Figure 1). It has to be noted that among the so-called
normal patterns, one had high peak values.
Individual cortisol patterns in ovarian cancer patients
(Figure 2) also showed two subgroups according to their
profile: (1) Fifteen patients had an abnormal profile of
cortisol and exhibited either high levels along the 24 h scale
and/or erratic peak and trough locations and/or flattened
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Figure 2 Patterns of serum cortisol in
cancer. (a), Normal profiles (n=5).
(n= 15).
24 04
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(b), Abnormal profiles
profiles. (2) Five patients displayed the so-called normal
cortisol pattern, i.e. peak at 08.00 then a progressive decline
and a trough at 00.00. However, it has to be underlined that
among these patterns, two of them showed low concentra-
tions all along the 24 h scale.
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Twenty-four h profiles of CEA
As shown in Table I, the mean values of the samples
obtained at 08.00 (basal value) were found elevated in ten out
of 13 breast cancer patients (range 7.6-336 ng ml-') and in
one out of eight ovarian cancer patients (141 ng ml-'),
whereas the cut-off value is <5 ng ml-'. Figures 3 and 4
display the individual profiles of serum CEA in breast and
ovarian cancer patients respectively.
In breast cancer patients, individual profiles of CEA
(Figure 3) did not follow a uniform trend and could exhibit a
variability as large as 20%. No relation between the
concentrations of CEA at 08.00 and cortisol pattern
subgroups could be seen (Kolmogorov-Smirnov chi-
square =2.223, P=0.6581).
The individual profiles of CEA in ovarian cancer patients
are shown in Figure 4. The only patient with elevated
concentration of plasma CEA had a small amplitude of
variation (around 10%) and the subgroup of patients with
concentrations below 5 ng ml-' most often showed erratic
profiles. No relation between the concentrations of CEA at
08.00 and cortisol pattern subgroups could be seen
(Kolmogorov-Smirnov chi-square- = 1.422, P=0.9822).
Twenty-four h profiles of CA 15-3 (breast cancer patients)
As shown in Table I, the mean values of the samples
obtained at 08.00 (basal value) were found elevated in any
patient for CA 15-3 (range 48-490 U ml-'), whereas the cut-
off value is <25 U ml-'.
The individual profiles of CA 15-3 also showed erratic
patterns whatever the subjects overall level (Figure 5), and
here again large 24 h variability was sometimes encountered.
No relation between the concentrations of CA 15-3 at 08.00
and cortisol pattern subgroups could be seen (Kolmogorov-
Smirnov chi-square =2.777, P=0.4989).
Twenty-four h profiles of CA 125 (ovarian cancer patients)
In 14 out of 20 ovarian cancer patients serum CA 125
concentrations at 08.00 were above the cut-off value of
35 U ml-' (Table I). Individual profiles of CA 125 in ovarian
cancer patients are shown in Figure 6. They were arbitrarily
dispatched into two subgroups, i.e. with levels below or
above 100 U ml-'. In both subgroups the serum CA 125
patterns were inconstant. In five out of 20 patients the peak
concentration was observed at 08.00, whereas in three others
it was their lowest one. No relation between the concentra-
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Figure 4 Twenty-four hour patterns of serum carcinoembryonic
antigen in eight patients with ovarian cancer.
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Figure 3 Twenty-four hour patterns of serum carcinoembryonic
antigen in 13 patients with breast cancer.
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Figure 5 Twenty-four hour patterns of serum CA15-3 in 13
patients with breast cancer.
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Figure 6 Twenty-four hour patterns of serum CA125 in 20
patients with ovarian cancer.
tions of CA 125 at 08.00 and cortisol pattern subgroups
could be seen (Kolmogorov-Smirnov chi-square = 1.067,
P >0.9999).
Discussion
Here we report data on the circadian patterns of serum
cortisol and tumour marker antigens in 13 patients with
advanced breast cancer and in 20 patients with ovarian
cancer.
It is now well accepted that the circadian periodicity of
cortisol secretion is an important signal for the synchronisation
of human temporal structure. Independently of the distinct
circadian peak coincident with the beginning ofthe organism's
activity cycle, another low-amplitude circadian peak may be
apparent in some individuals, following the midday meal and
located in the early afternooon (Quigley and Yen, 1982;
Follenius et al., 1982). Cortisol is therefore considered as a
strong oscillator, and thus as a marker of the circadian
rhythmicity in man (Touitou et al., 1982, 1983). Indeed,
except for endocrine diseases, such as Cushing's syndrome, in
which the circadian rhythm of cortisol is dramatically
disrupted, and psychiatric diseases, such as depression, in
which cortisol rhythm is present, although some of its
parameters, e.g. the nadir and the 24 h mean are modified,
cortisol rhythm is not altered by various factors, e.g. sex and
aging (Touitou et al., 1982, 1983). The changes in the secretory
pattern of serum cortisol reported here suggest a dramatic
rhythm modification: eight out ofthe 13 breast cancer patients
(53%) had abnormal patterns of the hormone with, e.g. a
flattened profile and/or shift in the peak or trough time, and/or
plateau with high values in the morning. In the same way, 15
out of 20 ovarian cancer patients (75%) had abnormal
secretory patterns of cortisol with either erratic peak and
trough time locations and/or low concentrations of the
hormone, and/or flattened profiles within the 24 h. Only five
patients could be considered as having a so-called normal
pattern, although two ofthem had low cortisol concentrations.
No relationship between cortisol subgroups and concentration
of tumour marker antigens in blood sampled at 08.00 could be
validated with Kolmogorov -Smirnov's test. Our data thus
point out the large prevalence of cortisol pattern alteration in
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breast and ovarian cancerpatients. It has to be emphasised that
considering mean group patterns results in masking the
phenomenon and that pooling the data usually allows
statistical validation (ANOVA, Cosinor) of a group circadian
rhythm of serum cortisol (Touitou et al., 1995), despite the
prevalence of erratic individual profiles. The observed pattern
modifications do not necessarily imply an alteration of the
organism's circadian clock. Besides, the physiopathological
consequences of such alterations are not yet known.
The circadian pattern of cortisol is closely related to that
of adrenocorticotrophic hormone (ACTH) and other
proopiomelanocortin-related hormones like /3-endorphin
(Gennazzani et al., 1983). Recently, interleukin 1 (Dunn,
1990) and interleukin 6 (Sala et al., 1990) have been added to
the list ofmolecules dealing with ACTH secretion and action.
Since an immunomodulatory circuit has been hypothesised to
operate between lymphocytes and hypothalamic-pituitary-
adrenal axis (Gatti et al., 1994), the modifications reported
here of cortisol circadian patterns may be related to changes
in the immunological status of the patients. A number of
other hypotheses may be raised for the origin of the
alteration or masking of serum cortisol rhythm. It might be
a consequence of a depressive state in cancer patients, but it
is known that in depressive patients the alterations in plasma
cortisol rhythm are only shifts in time of peak or trough
concentrations without rhythm disruption (Kripke et al.,
1994). It could also be caused by a poor synchronisation of
the patients related to a reduced diurnal activity and/or an
alteration of sleep caused by pain and/or anxiety. Lastly, one
cannot rule out a role played by the cancer itself with a
possibility of erratic secretion of hormone-like substances by
the tumour or its metastases.
In neither breast nor ovarian cancer patients could a
relationship be found between so-called normal and
abnormal serum cortisol patterns and morning concentra-
tions of tumour marker antigens. This study allowed us to
demonstrate a large variability in the 13 breast cancer
patients in the individual patterns of the serum concentra-
tion of CEA and CA 15-3, two tumour marker antigens most
commonly used in the follow-up of this pathology. The
amplitude of these variations during the 24 h of sampling
averaged 10-15%, but in some patients it could reach 30-
50%. For instance, it is remarkable that the extreme values,
within 24 h, of serum CA 15-3 serum concentrations could
range, e.g. from 400 to 640 U ml-' (patient BR) and from 90
to 120 U ml-1 (patient MP). These amplitudes were thus
much greater than those observed in other patients. In the
same way, extreme values for serum CEA could range from
336 to 400 ng ml-' in patient SF.
Antigen CA 125 is the elective tumour marker in ovarian
cancer since about 80% of the patients with non-mucinous
ovarian cancer have elevated blood concentrations. In the
present study, 14 out of 20 ovarian cancer patients had serum
concentrations of CA 125 exceeding the cut-off value of
35 U ml-'. It has to be noted that within the 24 h the
difference between the lowest and the highest concentration
observed in a given subject could be as large as 70%,
irrespective of the mean concentration. For example, in.
patients with elevated levels of the marker, serum concentra-
tions varied from 269 to 427 U ml-' (subject COU) or from
175 to 300 U ml-' (subject NIC). This study is, to our
knowledge, the first one dealing with the circadian variation
of serum CA 125 in ovarian cancer and showing that, besides
the modifications of the marker in non-malignant pathologies
(Touitou and Bogdan, 1988), large variations of serum CA
125 can be observed within 24 h which are not related to an
alteration of the clinical state of the patients, although this
does not occur in the majority of cases.
Serum CEA could be documented in only eight out of the
20 ovarian cancer patients and only one had a high serum
concentration of the marker. In this reduced set of ovarian
cancer patients the variability of serum CEA did not exceed
10%, but it cannot be guaranteed that larger variations could
not be encountered in a larger set of patients.
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The abnormalities observed in this study are coherent with
the hypothesis of an alteration of rhythms as already
observed in other types of cancer (Focan et al., 1986a;
Touitou et al., 1995; Gautherie and Gros, 1977; Klevecz et
al., 1987; Voutilainen, 1953). Our data on the variability of
serum tumour marker antigen concentrations may express the
evolutionary potential of the tumour and show that within
24 h, a 50% variability of serum concentration of a tumour
marker may be only a temporary consequence of this
evolution without apparent noticeable modification of the
patient's clinical condition. On the other hand, marker
antigens from solid tumours are stocked within the
intercellular spaces. Therefore, the variability of the plasma
concentration of these tumour markers as observed along the
24 h scale may reflect phenomena of a different nature from
that of a circadian organisation.
In conclusion, cortisol is a marker ofcircadian rhythmicity
allowing assessment of a subject's synchronisation, and our
study shows for the first time that 22 out of 33 cancer
patients have deeply altered serum cortisol circadian profiles.
These data, documenting a rhythm disruption in breast and
ovarian cancer patients, may be of interest in designing
chronotherapy protocols since they are based upon a reliable
link between clock time and the timing of the patient's
functions. The rhythm alterations reported here thus raise the
question of the uniformity of the time schedule of drug
administration in such patients. Further studies will be
necessary to establish if the resynchronisation of patients
with rhythm alterations should be a prerequisite for efficient
chronotherapy or would be a consequence of successful
chronotherapy.
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